Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 sept. 2018 02h00 HE | Source: Verona Pharma plc

Verona Pharma to Host Investor & Analyst R&D Forum on October 12, 2018

LONDON, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
20 sept. 2018 11h49 HE | Source: Verona Pharma plc

Issue of Shares & PDMR Announcement

LONDON, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
13 sept. 2018 08h00 HE | Source: Verona Pharma plc

Verona Pharma to Host Conference Call to Review Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD Presented at European Respiratory Society International Congress

LONDON, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
12 sept. 2018 02h00 HE | Source: Verona Pharma plc

Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International Congress

LONDON, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
06 sept. 2018 02h00 HE | Source: Verona Pharma plc

Verona Pharma Announces Publication of Key Paper on RPL554 in COPD in the European Respiratory Journal

LONDON, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
10 août 2018 07h12 HE | Source: Verona Pharma plc

Verona Pharma plc : PDMR Dealing & Issue of Shares

LONDON, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
07 août 2018 02h00 HE | Source: Verona Pharma plc

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018

Significant progress with RPL554 as potential treatment for COPD and CF Recently initiated important Phase 2 trial as add-on to dual bronchodilator therapy for COPD maintenance treatment LONDON,...
01 août 2018 02h00 HE | Source: Verona Pharma plc

Verona Pharma Initiates Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment

This three-way crossover study will inform design of pivotal Phase 3 trials Top line data expected first quarter 2019 LONDON, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)...
26 juil. 2018 08h30 HE | Source: Verona Pharma plc

Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2018 and Provide Clinical Development Update

LONDON, July 26, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
24 juil. 2018 08h30 HE | Source: Verona Pharma plc

Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare Conference

LONDON, July 24, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...

Page précédente